Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

Most Read from BloombergHousing’s Worst Crisis in Decades Reverberates Through 2024 RaceFrom Louisville, a Push to Plant ...

One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

Open Polytechnic, a business division of Te Pūkenga, and New Zealand’s specialist provider of online and distance learning, recently published its annual Research Report for 2023.

A drug that delivers chemotherapy directly to tumors has shown impressive activity against some of the hardest-to-reach cancer cells: those that have spread to the brain in patients with advanced HER2 ...

Agenus Inc. ("Agenus") , a leader in developing novel immunological agents to treat various cancers, presented data today at the European Society for Medical Oncology (ESMO) Congress held in Barcelona ...

CureVac N.V. ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first clinical ...

According to the companies, an objective response rate of 54.8% was observed with Daiichi Sankyo and Merck's ifinatamab deruxtecan at ... IDeate-Lung02 Phase 3 study. Mark Rutstein, MD, Global ...

hosted by the International Association for the Study of Lung Cancer. Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed antibody drug conjugate (ADC ...